Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Akari Therapeutics PLC (AKTX : NSDQ)

• Company Description    Akari Therapeutics PLC is a biopharmaceutical company. It focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. The Company's lead drug consist of Coversin is a recombinant small protein, which acts on complement component-C5, preventing release of C5a and formation of C5b-9. Akari Therapeutics PLC, formerly known as Celsus Therapeutics Plc, is based in London, United Kingdom. Number of Employees: 6

• Price / Volume Information    Yesterday's Closing Price: $18.27 Daily Weekly Monthly 20 Day Moving Average: 339,813 shares Shares Outstanding: 1.14 (millions) Market Capitalization: $20.91 (millions) Beta: 0.64 52 Week High: $56.80 52 Week Low: $3.02 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 204.50% 189.63% 12 Week 76.22% 62.90% Year To Date 58.05% -59.12%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 401 EAST JACKSON STREET SUITE 3300 - TAMPA,FL 33602 GBR ph: 929-274-7510 fax: 646-843-9352 info@akaritx.com http://www.akaritx.com

• General Corporate Information    Officers Samir R. Patel - President and Chief Executive Officer Hoyoung Huh - Chairman Torsten Hombeck - Chief Financial Officer Ray Prudo - Director James Neal - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00972G405 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/12/26 Share - Related Items Shares Outstanding: 1.14 Most Recent Split Date: 3.00 (0.03:1) Beta: 0.64 Market Capitalization: $20.91 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.45 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -123.29 12/31/25 - -70.34 09/30/25 - -68.38 ROA 03/31/26 - -63.01 12/31/25 - -35.46 09/30/25 - -31.89 Current Ratio 03/31/26 - 0.27 12/31/25 - 0.44 09/30/25 - 0.19 Quick Ratio 03/31/26 - - 12/31/25 - 0.44 09/30/25 - 0.19 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 12.56 12/31/25 - 24.75 09/30/25 - 27.82 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©